Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SANOFI INDIA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SANOFI INDIA CIPLA/
SANOFI INDIA
 
P/E (TTM) x 36.3 42.5 85.4% View Chart
P/BV x 4.2 8.7 48.7% View Chart
Dividend Yield % 0.5 1.0 48.2%  

Financials

 CIPLA   SANOFI INDIA
EQUITY SHARE DATA
    CIPLA
Mar-20
SANOFI INDIA
Dec-18
CIPLA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs5866,840 8.6%   
Low Rs3574,630 7.7%   
Sales per share (Unadj.) Rs207.01,203.1 17.2%  
Earnings per share (Unadj.) Rs18.6165.3 11.3%  
Cash flow per share (Unadj.) Rs33.2209.9 15.8%  
Dividends per share (Unadj.) Rs4.0084.00 4.8%  
Dividend yield (eoy) %0.81.5 58.0%  
Book value per share (Unadj.) Rs195.5963.6 20.3%  
Shares outstanding (eoy) m806.3523.03 3,501.3%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.34.8 47.7%   
Avg P/E ratio x25.334.7 73.0%  
P/CF ratio (eoy) x14.227.3 52.0%  
Price / Book Value ratio x2.46.0 40.5%  
Dividend payout %21.550.8 42.3%   
Avg Mkt Cap Rs m379,912132,078 287.6%   
No. of employees `00025.83.3 782.9%   
Total wages/salary Rs m30,2704,068 744.1%   
Avg. sales/employee Rs Th6,459.68,393.8 77.0%   
Avg. wages/employee Rs Th1,171.21,232.4 95.0%   
Avg. net profit/employee Rs Th580.21,153.0 50.3%   
INCOME DATA
Net Sales Rs m166,94927,708 602.5%  
Other income Rs m3,442897 383.7%   
Total revenues Rs m170,39128,605 595.7%   
Gross profit Rs m32,0606,235 514.2%  
Depreciation Rs m11,7471,027 1,143.8%   
Interest Rs m1,9747 28,194.3%   
Profit before tax Rs m21,7826,098 357.2%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,3122,292 275.4%   
Profit after tax Rs m14,9953,806 394.0%  
Gross profit margin %19.222.5 85.3%  
Effective tax rate %29.037.6 77.1%   
Net profit margin %9.013.7 65.4%  
BALANCE SHEET DATA
Current assets Rs m117,03815,922 735.1%   
Current liabilities Rs m43,9316,235 704.6%   
Net working cap to sales %43.835.0 125.3%  
Current ratio x2.72.6 104.3%  
Inventory Days Days9664 150.4%  
Debtors Days Days8521 407.7%  
Net fixed assets Rs m107,4247,539 1,424.9%   
Share capital Rs m1,613230 701.1%   
"Free" reserves Rs m156,01821,962 710.4%   
Net worth Rs m157,63022,192 710.3%   
Long term debt Rs m23,6930-   
Total assets Rs m236,62629,839 793.0%  
Interest coverage x12.0872.1 1.4%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.9 76.0%   
Return on assets %7.212.8 56.1%  
Return on equity %9.517.2 55.5%  
Return on capital %12.827.5 46.7%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,0367,587 738.6%   
Fx outflow Rs m6,7647,145 94.7%   
Net fx Rs m49,272442 11,147.5%   
CASH FLOW
From Operations Rs m30,6853,739 820.7%  
From Investments Rs m1,040-731 -142.3%  
From Financial Activity Rs m-29,488-1,972 1,495.3%  
Net Cashflow Rs m2,3401,036 225.9%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 60.4 34.4%  
Indian inst/Mut Fund % 12.2 14.4 84.7%  
FIIs % 23.7 14.6 162.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.5 249.5%  
Shareholders   161,166 15,184 1,061.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   TTK HEALTHCARE  ALEMBIC  DR. REDDYS LAB  ELDER PHARMA  SUVEN LIFE SCIENCES  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 15, 2021 (Close)

TRACK CIPLA

CIPLA - GSK PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS